BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, May 16, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Regulatory actions for Nov. 16, 2020

Nov. 16, 2020
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Chembio, Sofwave.
Read More

Other news to note for Nov. 16, 2020

Nov. 16, 2020
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aspen Dental Management, B. Braun Melsungen, Baxter, Cape Biologix, Clearchoice, Diabeloop, Grifols, Inno-3B, Intralink-Spine, Masimo, Medicrea, Medtronic, Nuprobe, Plantform, Procept Biorobotics, Qiagen, Start Codon, Sun Capital Partners, Terumo.
Read More
COVID-19 mRNA vaccine vials, syringe

Dynamic stability: Moderna flies high with storage-friendly COVID-19 vaccine bid

Nov. 16, 2020
By Randy Osborne
Moderna Inc.’s phase III win with its COVID-19 vaccine candidate, mRNA-1273, lifted spirits while validating the Cambridge, Mass.-based firm’s platform, as Wall Street buzzed with comparisons between the prospects that have yielded late-stage data thus far.
Read More
Janssen’s vaccine candidate

J&J targets U.K. for second study, as early data start flowing from COVID-19 vaccine trials

Nov. 16, 2020
By Nuala Moran
LONDON – A second phase III trial of Johnson & Johnson’s adenoviral-vectored COVID-19 vaccine is starting in the U.K. this week, amid concerns the positive news from the Pfizer Inc./Biontech SE vaccine study will deter volunteers from coming forward to take part.
Read More

Regulatory actions for Nov. 16, 2020

Nov. 16, 2020
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: 3D, Agilent, Alphamab, Amylyx, Artelo, Aruvant, Boehringer, Cytodyn, Dicerna, Eisai, Exegi, Innovation, Insmed, Kiniksa, Jounce, Lilly, Lupin, Merck, Mindmed, Neoimmunetech, Neuronasal, Sanofi, Tracon.
Read More

Other news to note for Nov. 16, 2020

Nov. 16, 2020
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 9 Meters, Abpro, Aeterna, Agbiome, AIkido Amag, Assembly, Biohaven, Bone, Catalent, Covis, Dicerna, Door, Elevatebio, IEH, Innocan, Johnson & Johnson, Kala, Lead, Lifeedit, Lilly, Merck & Co., Minoryx, Mylan, Pfizer, Pharvaris, Prime, PTC, Receptor, Roche, Synthetic Biologics, Vertex, Viatris, Vivus, Xoma, Xortx.
Read More

In the clinic for Nov. 16, 2020

Nov. 16, 2020
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adverum, Akebia, Alligator, Aptevo, Atara, Beyondspring, Bioaegis, Biological E., Calypso, Cerevance, Dynavax, Genenta, Intravacc, Karyopharm, Kodiak, Moderna, Medexus, Obseva, Precigen, PTC, Rapt, Redhill, Revelation, Rhovac.
Read More
Regulatory front

Vaccine, diagnostic developers targeted by cyberattacks

Nov. 16, 2020
By Mari Serebrov
The latest global regulatory news, changes and updates affecting biopharma, including: Lawmakers protest latest 340B scheme; Groups make case for extending sequester moratorium; More $$ needed for global vaccine effort; Russia extends COVID-19 drug, device program.
Read More
Coronavirus and DNA

RNA drugging strategies beyond oligos shaping up

Nov. 16, 2020
By Anette Breindl
A Polish/Dutch team of investigators has reported new insights into the structure of the SARS-CoV-2 genome that suggests it could be amenable to both small-molecule and oligonucleotide drugs.
Read More
Australian flag on laptop screen with health professional
Australia’s National Digital Health Initiative

Australia’s distance not a disadvantage when it comes to digital health technologies

Nov. 13, 2020
By Tamra Sami
PERTH, Australia – The COVID-19 pandemic has highlighted the importance of digital health technology, and the Australian government quickly enabled programs in telehealth and e-prescriptions. It now is embracing opportunities to build on this momentum to accelerate the country’s economic digital transformation. Not only will this transformation contribute to Australia’s recovery, but also to its long-term prosperity, said Sue MacLeman, chair of Australia’s Medical Technologies and Pharmaceuticals Industry Growth Centre (MTPConnect), during a recent ANDHealth teleconference.
Read More
Previous 1 2 … 334 335 336 337 338 339 340 341 342 … 552 553 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 15, 2026.
  • Illustration of a glowing circle to represent circRNA

    ASGCT 2026: Circular RNA, the new beast in gene and cell therapy

    BioWorld
    Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
  • Test tubes, dropper and capsules

    Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal

    BioWorld
    In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 12, 2026
  • 3D illustration of adeno-associated viruses

    ASGCT 2026: Uncovering the mechanisms of AAV toxicity

    BioWorld
    Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing